Intraclass Difference in Pneumonia Risk with Fluticasone and Budesonide in COPD: A Systematic Review of Evidence from Direct-Comparison Studies

References

• SuissaS, PatenaudeV, LapiF, ErnstP. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036. doi:10.1136/thoraxjnl-2012-20287224130228
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (2020 report). 2020.
   Google Scholar
• CalverleyPM, AndersonJA, CelliB, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa06307017314337
   PubMed Web of Science ®Google Scholar
• SharafkhanehA, SouthardJG, GoldmanM, UryniakT, MartinUJ. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study. Respir Med. 2012;106(2):257–268. doi:10.1016/j.rmed.2011.07.02022033040
   PubMed Web of Science ®Google Scholar
• ErnstP, GonzalezAV, BrassardP, SuissaS. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176(2):162–166. doi:10.1164/rccm.200611-1630OC17400730
   PubMed Web of Science ®Google Scholar
• CrimC, CalverleyPM, AndersonJA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34(3):641–647. doi:10.1183/09031936.0019390819443528
   PubMed Web of Science ®Google Scholar
• KardosP, WenckerM, GlaabT, VogelmeierC. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175(2):144–149. doi:10.1164/rccm.200602-244OC17053207
   PubMed Web of Science ®Google Scholar
• AnzuetoA, FergusonGT, FeldmanG, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009;6(5):320–329. doi:10.1080/1541255090314088119863361
   PubMedGoogle Scholar
• SorianoJB, VisickGT, MuellerovaH, PayvandiN, HansellAL. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest. 2005;128(4):2099–2107. doi:10.1378/chest.128.4.209916236861
   PubMed Web of Science ®Google Scholar
• RestrepoMI, SibilaO, AnzuetoA. Pneumonia in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis (Seoul). 2018;81(3):187–197. doi:10.4046/trd.2018.003029962118
   PubMed Web of Science ®Google Scholar
• WedzichaJA, CalverleyPM, SeemungalTA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177(1):19–26. doi:10.1164/rccm.200707-973OC17916806
   PubMed Web of Science ®Google Scholar
• RennardSI, TashkinDP, McElhattanJ, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–565. doi:10.2165/00003495-200969050-0000419368417
   PubMed Web of Science ®Google Scholar
• TashkinDP, RennardSI, MartinP, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68(14):1975–2000. doi:10.2165/00003495-200868140-0000418778120
   PubMed Web of Science ®Google Scholar
• LipsonDA, BarnacleH, BirkR, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC28375647
   PubMed Web of Science ®Google Scholar
• YangM, DuY, ChenH, JiangD, XuZ. Inhaled corticosteroids and risk of pneumonia in patients with chronic obstructive pulmonary disease: a meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;77:105950. doi:10.1016/j.intimp.2019.10595031629940
   PubMed Web of Science ®Google Scholar
• YangHH, LaiCC, WangYH, et al. Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist. Int J Chron Obstruct Pulmon Dis. 2017;12:2477–2485. doi:10.2147/COPD.S13903528860742
   PubMed Web of Science ®Google Scholar
• JansonC, LarssonK, LisspersKH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306. doi:10.1136/bmj.f330623719639
   PubMed Web of Science ®Google Scholar
• RobertsM, MapelD, PetersenH, BlanchetteC, RamachandranS. Comparative effectiveness of budesonide/formoterol and fluticasone/salmeterol for COPD management. J Med Econ. 2011;14(6):769–776. doi:10.3111/13696998.2011.62281721942463
   PubMedGoogle Scholar
• KernDM, DavisJ, WilliamsSA, et al. Comparative effectiveness of budesonide/formoterol combination and fluticasone/salmeterol combination among chronic obstructive pulmonary disease patients new to controller treatment: a US administrative claims database study. Respir Res. 2015;16:52. doi:10.1186/s12931-015-0210-x25899176
   PubMed Web of Science ®Google Scholar
• HiranoR, FujitaM, MatsumotoT, OnR, WatanabeK. Inhaled corticosteroids might not increase the risk of pneumonia in patients with chronic obstructive pulmonary disease in Japan. Int J Chron Obstruct Pulmon Dis. 2018;13:3503–3509. doi:10.2147/COPD.S18034930498340
   PubMed Web of Science ®Google Scholar
• APhA. Focus on COPD: Pharmacists Helping Patients Improve Outcomes and Reduce Readmissions. 2017 Available from: https://www.pharmacist.com/focus-copd. Accessed October 7, 2020.
   Google Scholar
• SuissaS. Number needed to treat in COPD: exacerbations versus pneumonias. Thorax. 2013;68(6):540–543. doi:10.1136/thoraxjnl-2012-20270923125170
   PubMed Web of Science ®Google Scholar
• World Health Organization. Burden of COPD. Available from: https://www.who.int/respiratory/copd/burden/en/. Accessed 4 15, 2019.
   Google Scholar
• World Health Organization. Chronic obstructive pulmonary disease (COPD). 2017 Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd). Accessed 415, 2019.
   Google Scholar
• NiewoehnerDE, ErblandML, DeupreeRH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340(25):1941–1947. doi:10.1056/NEJM19990624340250210379017
   PubMed Web of Science ®Google Scholar
• Van AndelAE, ReisnerC, MenjogeSS, WitekTJ. Analysis of inhaled corticosteroid and oral theophylline use among patients with stable COPD from 1987 to 1995. Chest. 1999;115(3):703–707. doi:10.1378/chest.115.3.70310084479
   PubMed Web of Science ®Google Scholar
• RamirezJA, WiemkenTL, PeyraniP, et al. Adults hospitalized with pneumonia in the United States: incidence, epidemiology, and mortality. Clin Infect Dis. 2017;65(11):1806–1812. doi:10.1093/cid/cix64729020164
   PubMed Web of Science ®Google Scholar
• FesticE, ScanlonPD. Incident pneumonia and mortality in patients with chronic obstructive pulmonary disease. A double effect of inhaled corticosteroids? Am J Respir Crit Care Med. 2015;191(2):141–148. doi:10.1164/rccm.201409-1654PP25409118
   PubMed Web of Science ®Google Scholar
• WangCY, LaiCC, YangWC, et al. The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients’ life quality with COPD in Taiwan (IMPACT) study. Int J Chron Obstruct Pulmon Dis. 2016;11:2775–2783.27877031
   PubMed Web of Science ®Google Scholar
• SuissaS, CoulombeJ, ErnstP. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of pneumonia. Chest. 2015;148(5):1177–1183. doi:10.1378/chest.15-062726110239
   PubMed Web of Science ®Google Scholar
• Maassen van den BrinkKI, BoorsmaM, Staal-van den BrekelAJ, EdsbäckerS, WoutersEF, ThorssonL. Evidence of the in vivo esterification of budesonide in human airways. Br J Clin Pharmacol. 2008;66(1):27–35. doi:10.1111/j.1365-2125.2008.03164.x18384442
   PubMed Web of Science ®Google Scholar
• DalbyC, PolanowskiT, LarssonT, BorgstromL, EdsbackerS, HarrisonTW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10:104. doi:10.1186/1465-9921-10-10419878590
   PubMed Web of Science ®Google Scholar
• TashkinDP, StrangeC. Inhaled corticosteroids for chronic obstructive pulmonary disease: what is their role in therapy? Int J Chron Obstruct Pulmon Dis. 2018;13:2587–2601. doi:10.2147/COPD.S17224030214177
   PubMed Web of Science ®Google Scholar
• ProvostKA, SmithM, Miller-LarssonA, GudleskiGD, SethiS. Bacterial regulation of macrophage bacterial recognition receptors in COPD are differentially modified by budesonide and fluticasone propionate. PLoS One. 2019;14(1):e0207675. doi:10.1371/journal.pone.020767530677037
   PubMed Web of Science ®Google Scholar
• JansonC, StratelisG, Miller-LarssonA, HarrisonTW, LarssonK. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:3055–3064. doi:10.2147/COPD.S14365629089754
   PubMed Web of Science ®Google Scholar
• AndrejakC, NielsenR, ThomsenVO, DuhautP, SorensenHT, ThomsenRW. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax. 2013;68(3):256–262. doi:10.1136/thoraxjnl-2012-20177222781123
   PubMed Web of Science ®Google Scholar
• BrodeSK, CampitelliMA, KwongJC, et al. The risk of mycobacterial infections associated with inhaled corticosteroid use. Eur Respir J. 2017;50(3):1700037. doi:10.1183/13993003.00037-2017
   Web of Science ®Google Scholar
• LarssonK, JansonC, LisspersK, et al. Combination of budesonide/formoterol more effective than fluticasone/salmeterol in preventing exacerbations in chronic obstructive pulmonary disease: the PATHOS study. J Intern Med. 2013;273(6):584–594. doi:10.1111/joim.1206723495860
   PubMed Web of Science ®Google Scholar